Document Detail


Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
MedLine Citation:
PMID:  22456299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Granulocyte colony-stimulating factors (G-CSF), are available for prevention of neutropenia and reduction of its complications in cytostatic chemotherapy. The purpose of this analysis was to determine the consumption rates for various G-CSF and to compare outpatient medication costs per patient and treatment cycle.
METHODS: Prescription data of statutory health insurance members in Germany (IMS®LRx database) with G-CSF prescriptions between January 2008 and July 2010 were evaluated. A period of observation of at least 6 months prior to and after the G-CSF prescription was required.
RESULTS: Prescription data of 8,726 patients treated with original filgrastim, 4,240 with biosimilar filgrastim, 6,456 with lenograstim, and 9,939 with pegfilgrastim were analyzed. The regression model showed statistically significant costreducing effects per cycle for treatment with lenograstim compared with non-lenograstim (-0.47 vs. original filgrastim; -0.15 vs. biosimilar filgrastim; -1.04 vs. pegfilgrastim; each p < 0.0001). This result has been adjusted for patient age, gender, number of injections, and prescribing specialist group.
CONCLUSIONS: Treatment with the original preparation lenograstim is significantly cheaper compared to the other two original drugs and biosimilar. The costs of G-CSF treatment with the original preparation lenograstim and the filgrastim biosimilars are in a similar range, but with a significantly lower cost for lenograstim. Compared to their reference product the biosimilars thus show a cost advantage.
Authors:
Peyman Hadji; Karel Kostev; Detlef Schröder-Bernhardi; Volker Ziller
Related Documents :
11464059 - Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: lon...
15947609 - Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers s...
17320669 - Cryoablation as primary treatment for localized prostate cancer followed by penile reha...
12496909 - Haematuria associated with bph-natural history and a new treatment option.
12352419 - Transurethral holmium laser enucleation versus transvesical open enucleation for prosta...
11186469 - Day-case local anaesthetic radiofrequency thermal ablation of benign prostatic hyperpla...
15303999 - Investigational use of ribavirin in the treatment of severe acute respiratory syndrome,...
21670709 - Are polyaxially locked screws advantageous in the plate osteosynthesis of proximal hume...
19484469 - Ultrasound-guided injection of triamcinolone and bupivacaine in the management of de qu...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  50     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-29     Completed Date:  2012-05-24     Revised Date:  2012-08-30    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  281-9     Citation Subset:  IM    
Affiliation:
Philipps-University of Marburg, Germany. Peyman.Hadji@t-online.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Ambulatory Care / economics*
Biosimilar Pharmaceuticals / economics*,  therapeutic use*
Cost Savings
Cost-Benefit Analysis
Databases as Topic
Drug Costs*
Drug Prescriptions / economics
Female
Germany
Granulocyte Colony-Stimulating Factor / economics*,  therapeutic use*
Humans
Insurance, Pharmaceutical Services / economics
Male
Middle Aged
Models, Economic
Neutropenia / drug therapy*,  economics*
Outcome and Process Assessment (Health Care) / economics*
Recombinant Proteins / economics,  therapeutic use
Regression Analysis
State Medicine / economics
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biosimilar Pharmaceuticals; 0/Recombinant Proteins; 0/pegfilgrastim; 121181-53-1/Filgrastim; 135968-09-1/lenograstim; 143011-72-7/Granulocyte Colony-Stimulating Factor
Comments/Corrections
Erratum In:
Int J Clin Pharmacol Ther. 2012 Jul;50(7):532

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients.
Next Document:  QT effect of semagacestat at therapeutic and supratherapeutic doses.